Fixed-Duration Options for CLL

Now Viewing

EP: 1.Fixed-Duration Options for CLL

EP: 2.Pirtobrutinib in the BRUIN CLL-321 Study

EP: 3.Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape

EP: 4.Sequencing Considerations in Relapsed/Refractory CLL

EP: 5.Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL

EP: 6.Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL

EP: 7.The Inflation Reduction Act and Cost Considerations for BTK Inhibitors

EP: 8.Switching Between BTK Inhibitors in CLL

EP: 9.Discontinuing Versus Switching BTK Inhibitors for Toxicity

EP: 10.Opportunities for Easing BTK Inhibitor Switches

EP: 11.Reflections on 2024’s Progress in R/R CLL

Content above is prompted by the following:

• A key distinction between preferred upfront therapies for CLL—venetoclax-based regimens and Bruton tyrosine kinase (BTKi)–based regimens—is that venetoclax offers a fixed-duration option, while BTKi therapy is typically continuous. However, studies presented at the 2024 American Society of Hematology annual meeting explored the efficacy and safety of fixed-duration BTKi therapy in the first-line setting. How might adopting fixed-duration BTKi therapy influence treatment choices in the relapsed/refractory CLL setting?